Participants 104 165 4
progressive, metastatic, castration-resistant prostate cancer
Participants 346 489 6
Men with progressive mCRPC after docetaxel-based chemotherapy were randomly assigned 2:1 to receive sunitinib 37.5 mg/d continuously or placebo
Participants 712 800 6
873 patients were randomly assigned to receive sunitinib (n = 584) or placebo (n = 289).
